Medicus Pharma Ltd.

Medicus Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutic programs for dermatological conditions. The company's primary development candidate is SKNJCT-003, currently in Phase 2 clinical evaluation for basal cell carcinoma treatment. In addition, Medicus Pharma maintains a strategic collaboration with the Gorlin Syndrome Alliance to support access to SKINJECT for patients with Gorlin Syndrome, a rare genetic disorder associated with increased skin cancer risk.

The company was incorporated in Ontario, Canada in 2008 and underwent a name change from Interactive Capital Partners Corporation to Medicus Pharma Ltd. in September 2023. Medicus Pharma is headquartered in Conshohocken, Pennsylvania and maintains operations in the United States. As a development-stage biotech firm with limited commercial operations, the company has not generated significant revenue from product sales to date.